By large-scale genome sequencing analysis of HCC, the core drivers (TERT, TP53, and CTNNB1/AXIN1) have been identified as initial molecular events and other low-frequency drivers including therapeutically targetable drivers. This evidence concerns the gene TP53 and hepatocellular carcinoma.